Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GenMont BiotechTPE:3164 82 EV-to-EBIT is 14.07 as of Aug. 23, 2026, which is 35% below its 10-year median of 21.66. GuruFocus rates TPE:3164 with a GF Score™ of 82/100 and a GF Value™ of NT$21.02 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 376 Biotechnology companies, GenMont Biotech ranks better than 53.46% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
GenMont Biotech's Enterprise Value for the quarter that ended in Jun. 2026 was NT$1,194.3 Mil.
GenMont Biotech's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$84.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GenMont Biotech EV-to-EBIT Related Terms
GenMont Biotech EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for GenMont Biotech's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:3164 vs VRTX, REGN, RVMD: EV-to-EBIT Comparison
For the Biotechnology subindustry, GenMont Biotech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GenMont Biotech EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, GenMont Biotech's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where GenMont Biotech's EV-to-EBIT falls into.
GenMont Biotech's current Enterprise Value is NT$1,194.3 Mil.
GenMont Biotech's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$84.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GenMont Biotech (TPE:3164) has a EV-to-EBIT of 14.07 as of Aug. 23, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on GenMont Biotech and its competitors. This is 35% below median its historical median of 21.66. According to the industry distribution chart, GenMont Biotech ranks #175 out of 376 companies in the Biotechnology industry, placing it in the top 46.5%.
Is GenMont Biotech's EV-to-EBIT too high?
GenMont Biotech's current EV-to-EBIT of 14.07 is 35% below median its 10-year median of 21.66. The Biotechnology industry median EV-to-EBIT is 16.16. GenMont Biotech's value of 14.07 is 12.9% below this industry median. Based on the distribution chart, GenMont Biotech ranks #175 out of 376 companies in the Biotechnology industry, which is above the industry midpoint. Overall, GenMont Biotech has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does GenMont Biotech's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, GenMont Biotech ranks #175 out of 376 companies for EV-to-EBIT. This puts GenMont Biotech in the upper half of its industry. The industry median EV-to-EBIT is 16.16. GenMont Biotech's value of 14.07 is 12.9% below this benchmark. While the company's 10-year median is 21.66 vs. the industry median of 16.16, GenMont Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 16.16, based on 376 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GenMont Biotech's current EV-to-EBIT of 14.07 is 12.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on GenMont Biotech and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 16.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GenMont Biotech's current EV-to-EBIT is 14.07, which is 35% below median its own 10-year median of 21.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GenMont Biotech stock overvalued right now?
Based on GuruFocus' analysis, GenMont Biotech (TPE:3164) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$21.02, compared to a current price of NT$15.90 — trading 24.4% below its estimated fair value. The current EV-to-EBIT is 14.07, which is 35% below median its 10-year median of 21.66 and 12.9% below the Biotechnology industry median of 16.16. GenMont Biotech's overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For GenMont Biotech (TPE:3164), the current EV-to-EBIT is 14.07 as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GenMont Biotech (TPE:3164) Overvalued in 2026?
Based on GuruFocus' analysis, GenMont Biotech stock appears to be undervalued.
The current stock price of NT$15.90 is trading 24.4% below its estimated GF Value™ of NT$21.02.
GuruFocus considers GenMont Biotech to be Modestly Undervalued.
Key valuation signals for TPE:3164:
EV-to-EBIT: 14.07 (35% below median its 10-year median of 21.66)
GF Value™: NT$21.02 vs. price of NT$15.90 (24.4% below fair value)
Industry Position: 12.9% below the Biotechnology median (#175 of 376)
No single metric tells the full story. See the TPE:3164 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GenMont Biotech Inc is engaged in the research, development, manufacturing, and selling of a variety of probiotic supplements. The Group mainly engages in the manufacturing and selling of functional foods, its single operating segment.
82GF Score
Get the complete analysis for TPE:3164
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:3164 has been successfully added to your 
